What AiScreenings does

AiScreenings is a French medical technology company founded in 2017 and headquartered in Paris that develops AI-powered medical devices for diagnostic support in dermatology and ophthalmology. The company's core product is the ALICIA platform, a medical-grade telemedicine technology hub that integrates three proprietary AI medical devices: aiSkin-DT for melanoma detection from skin lesion images, aiVista-SD for multiclass diabetic retinopathy screening, and aiVista-DT for combined diabetic retinopathy and glaucoma detection from fundus photographs. The technology is built on computer vision models trained for medical image analysis, with API-ready interoperability and confidential electronic medical record capabilities, and the ALICIA Pro mobile application is available on both Google Play and Apple App Store.

The company operates as a B2B medical technology provider targeting healthcare professionals and medical institutions, with a go-to-market built on enterprise sales and strategic partnerships. Key commercial relationships include a co-developed product (Olyatis) with Les Laboratoires Servier using aiVista-SD technology, a Microsoft partner relationship for cloud infrastructure, and an October 2024 tripartite partnership with Topcon Healthcare and BeeKeeperAI to validate the aiVista AI model on the Harmony platform for U.S. market entry. The company is ISO 13485 certified for medical device quality management and has received non-dilutive funding from the EU's Horizon 2020 research and innovation programme (grant agreement No 886575). Revenue figures are not publicly disclosed, and the company maintains a lean team of 11-50 employees.

Name

AiScreenings

Legal name

AiScreenings

Website

https://aiscreenings.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

AiScreenings is a French medical technology company founded in 2017 that develops AI-powered medical devices for dermatology and ophthalmology diagnostics, serving healthcare professionals and institutions through its ALICIA telemedicine platform and proprietary aiSkin-DT, aiVista-SD, and aiVista-DT products.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Responsible AI, Security & Privacy Platforms (Safety, Guardrails, PII) (HDAEANAG), Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO)

Keywords

• AI medical imaging
• Dermatology diagnostics
• Ophthalmology screening
• Telemedicine platform
• Clinical decision support

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

AiScreenings develops and markets AI-powered medical devices for early diagnosis and treatment monitoring, focused on dermatology and ophthalmology. Its ALICIA® platform serves as a medical-grade technology hub that integrates three CE-marked AI medical devices—aiSkin-DT® (melanoma detection), aiVista-SD® (diabetic retinopathy), and aiVista-DT® (diabetic retinopathy and glaucoma)—to support healthcare professionals in medical image analysis, triaging, and telemedicine. The company also provides an API-ready collaborative platform enabling secure data exchange among doctors, specialists, and researchers.

Product overview

AiScreenings delivers a unified AI-powered medical technology platform centered on the ALICIA® telemedicine solution, which integrates multiple specialized medical devices for medical image analysis. The product portfolio includes three distinct AI medical devices: aiVista-SD® and aiVista-DT® for ophthalmology (diabetic retinopathy and glaucoma detection from fundus photographs), and aiSkin-DT® for dermatology (melanoma detection from skin lesion images). These devices share a common AI engine for computer vision analysis of medical images and are designed to interoperate through a collaborative platform enabling secure data sharing among doctors, specialists, and researchers.

Differentiator

Problem solved

Functional benefit

Brands

• ALICIA®: AI-Based Medical Devices Powered Telemedicine Solution - A medical grade technology hub enabling safe, fast and accurate diagnosis
• aiSkin-DT®
• aiVista-SD®
• aiVista-DT®
• ALICIA Pro

Products and services

• ALICIA® AI-based medical device powered telemedicine solution that serves as a smart companion supporting doctors in medical image diagnosis. Provides efficient, accurate, and reliable technology for early diagnosis and treatment monitoring across dermatology and ophthalmology; includes a collaborative platform for sharing among doctors, specialists, and researchers and an API-ready architecture for confidential data exchange.
• aiSkin-DT® Melanoma detection medical device for dermatology that analyzes skin lesion images to support early detection of skin cancer. Designed for healthcare professionals requiring AI-powered diagnostic support for dermatological screening.
• aiVista-SD® Multiclass diabetic retinopathy standalone medical device that enables early screening and detection of diabetic retinopathy from fundus photographs. Powers Olyatis™, a product developed in collaboration with Les Laboratoires Servier.
• aiVista-DT® Multiclass diabetic retinopathy and glaucoma detection medical device that analyzes fundus photographs for multiple ocular pathologies, enabling comprehensive eye disease screening for healthcare professionals.

Quantifiable outcome

• Medical-grade technology hub enabling safe, fast and accurate diagnosis

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• BeeKeeperAIcoreTechnology or Integration · 11 October 2024Strategic partnership with BeeKeeperAI to use their EscrowAI privacy-preserving collaboration platform for validating AiScreenings' aiVista AI diagnostic algorithms. The collaboration utilizes confidential computing technology to protect algorithm intellectual property while enabling validation on real-world healthcare data.
• Topcon HealthcarecoreStrategic or Co-development Partner · 11 October 2024Strategic partnership combining Topcon's cloud-based clinical image management platform Harmony with BeeKeeperAI's EscrowAI. The initial project enables AiScreenings to validate its aiVista AI diagnostic model on fundus photographs hosted on the Harmony platform in the U.S. market.
• MicrosoftcoreTechnology or IntegrationAiScreenings is a Microsoft partner headquartered in France, utilizing Microsoft's cloud infrastructure and healthcare technology ecosystem for its AI medical device platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• HeartFlow: AI-driven non-invasive cardiac diagnostics using imaging analysis. Comparable as an AI imaging diagnostics company with clinical workflow integration and reimbursement-driven adoption.
• Viz.ai: AI clinical workflow platform for stroke and other conditions; relevant adjacent peer operating in AI-enabled clinical decision support and imaging triage.
• Zebra Medical Vision (Nanox): AI radiology platform offering broad imaging diagnostics; represents a larger, broader-scope peer serving similar hospital customers with overlapping medical imaging AI capability.

Emerging players

• RetinAI Discovery (Ikerian AG): AI platform for ophthalmic data management and disease characterization. Closely overlaps AiScreenings' ophthalmology focus with an emphasis on fundus image analytics.
• Paige.AI: AI-based pathology diagnostics company. Comparable as an adjacent medical-imaging AI vendor pursuing clinical-decision-support use cases in healthcare.

Direct peers

• DermaSensor: FDA-authorized AI-enabled spectroscopy device for skin cancer detection at the point of care. Competes with AiScreenings in dermatology AI screening.
• Lunit: Medical imaging AI company with deep learning solutions for radiology and pathology; comparable as a multi-modality medical-imaging AI vendor targeting clinical decision support.
• SkinVision: AI-powered dermatology app for skin cancer risk assessment from smartphone images. Direct competitor to AiScreenings' aiSkin-DT melanoma detection offering.
• Digital Diagnostics (IDx-DR): Pioneer in autonomous AI for diabetic retinopathy detection (IDx-DR). Directly comparable to AiScreenings' aiVista-SD/DT ophthalmology offerings in target use case, regulatory pathway, and clinical buyer.
• AEYE Health: AI retinal screening for diabetic retinopathy and other ocular conditions, FDA-cleared. Closely overlaps AiScreenings' ophthalmology portfolio in product and clinical positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/aiscreenings
• LinkedInlinkedin.com/company/aivision-health
• Facebookfacebook.com/aiscreenings

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiScreenings